Latebreakers: Orphan drug acromegaly treatment wins FDA approval

Article

Somatuline Depot receives FDA approval for the treatment of acromegaly.

Lanreotide acetate injection (Somatuline Depot, Beaufour Ipsen/ Tercica) has been approved by the FDA for the long-term treatment of acromegaly, a disease characterized by abnormal secretion of growth hormone. The drug works by lowering levels of growth hormone and insulin-like growth factor-1, which stimulate bone and tissue growth and lead to enlargement of hands, feet, internal organs, and facial bones in patients with the disease. Lanreotide is administered as a subcutaneous injection once every four weeks for three months and will be available as 60-, 90-, and 120-mg prefilled syringes in about eight weeks, according to the manufacturer. The new treatment is indicated for patients who have not responded well to or are not candidates for surgery and/or radiotherapy.

Newsletter

Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.

Recent Videos
fake news misinformation | Image Credit: Bits and Splits - stock.adobe.com
© 2025 MJH Life Sciences

All rights reserved.